You are here

Article Text

Article menu
Download PDFPDF
Letter
Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema
  1. J B Jonas,
  2. I Kreissig,
  3. R F Degenring,
  4. B A Kamppeter
  1. Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Germany
  1. Correspondence to: Dr J Jonas Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; Jost.Jonasma.augen.uni-heidelberg.de

https://doi.org/10.1136/bjo.2004.050575

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Recent studies have suggested that intravitreal triamcinolone acetonide may be a treatment option for diffuse diabetic macular oedema.1 Since the duration of the effect of an intravitreal application of triamcinolone acetonide lasts between 4 weeks and up to 9 months,2,3 the purpose of this study was to evaluate the effect of a repeated intravitreal injection of triamcinolone acetonide.

    Case reports

    The clinical interventional case series study included four patients with diffuse diabetic macular oedema who consecutively received a second intravitreal injection of about 20 mg triamcinolone acetonide 7.6 (SD 3.9) …

    View Full Text

    Footnotes

    • Proprietary interest: none.